SUPER-DIALYSIS-Study: Supera Stent Interventions in Juxta-anastomotic (re)Stenosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Michael Lichtenberg, Dr.med.
- Phone Number: 201 +49 02923 952 242
- Email: M.Lichtenberg@klinikum-hochsauerland.de
Study Locations
-
-
-
Arnsberg, Germany, 59759
- Klinikum Hochsauerland GmbH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients must be ≥ 18 years of age, able to perform follow-up visits, have a life expectancy > 12 months.
- Hemodialysis patients undergoing endovascular angioplasty due to a clinically symptomatic stenosis (de novo or restenosis) of the juxta-anastomotic radiocephalic AVF with significant stenosis (lumen diameter < 2.7mm)
- Patients with at least one previous endovascular intervention to restore AVF function
- The target lesion consists of one or more lesions with a target lesion length of less than or equal to 80 mm in the juxta-anastomotic segment of the radiocephalic AVF
- The target blood vessel diameter of the target lesion is between 4.0 and 7.5 mm (in angiographic or ultrasound evaluation)
- If there are other non-target lesions, then non-target lesions must be successfully cured with a balloon before treating the target lesion
Exclusion Criteria:
- Patients with AVF stenosis observed and estimated as nonsignificant (lumen diameter > 2.7mm) or a vessel <4.0 and > 7.5 mm in diameter by visual estimation
- Patients with a known hypersensitivity or contraindication to anticoagulant/anti-platelet therapies, or sensitivity to contrast media that cannot be adequately pre-medicated.
- Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the study device.
- Patients that are currently participating in another clinical trial involving any investigational drug or device that may potentially confound the results of the study, or that would limit the patient's compliance with the follow-up requirements of the study.
- Prior enrolment in this trial
- Women who are pregnant or lactating
- Patients, who underwent a major surgery (such as thoracotomy, craniotomy, etc.) within 30 days prior to the study.
- Patients, who have scheduled a major surgery (such as thoracotomy, craniotomy, etc.). within 30 days after enrolment -
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
SUPERA peripheral stent system
|
The device will be employed for treatment of juxta-anastomotic stenosis in failing AV fistula after previous percutaneous angioplasty procedures
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with primary patency of juxta-anastomose at month 3
Time Frame: 3 months
|
Primary patency is defined as clinically assessed intervention free (IFP) period
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with primary patency of juxta-anastomose
Time Frame: 1, 6 and 12 months.
|
Primary patency is defined as clinically assessed intervention free (IFP) period
|
1, 6 and 12 months.
|
|
Number of patients with assisted primary patency
Time Frame: 1, 3, 6 and 12 months
|
Assisted primary patency is defined as interval until access thrombosis or the time of measurement of patency, including intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of a patent access
|
1, 3, 6 and 12 months
|
|
Number of patients with secondary patency
Time Frame: 1, 3, 6 and 12 months
|
Secondary patency is defined as interval until access abandonment, thrombosis, or the time of patency measurement including intervening manipulations (surgical or endovascular interventions) designed to reestablish functionality in thrombosed access
|
1, 3, 6 and 12 months
|
|
Number of patients with technical success
Time Frame: Day 1 after the index procedure
|
Residual stenosis < 30% after treatment with Supera stent (measured by angiography during the procedure)
|
Day 1 after the index procedure
|
|
Number of patients with procedural success
Time Frame: 1 day (discharge)
|
Residual stenosis < 30% with no major adverse events (MAE)
|
1 day (discharge)
|
|
Number of patients with clinical success
Time Frame: 1 day (discharge)
|
Hemodialysis access function improved, dialysis function restored, and at least one dialysis session completed after the procedure until discharge
|
1 day (discharge)
|
|
Number of patients with access circuit patency
Time Frame: 1,3,6,12 months
|
Freedom from development of a stenosis in any region of the AVF circuit, including the juxta-anastomotic segment
|
1,3,6,12 months
|
|
Recirculation rate
Time Frame: 1, 3, 6 and 12 months
|
1, 3, 6 and 12 months
|
|
|
Fistula flow
Time Frame: 1, 3, 6 and 12 months
|
Flow in AV fistula measured with ultrasound
|
1, 3, 6 and 12 months
|
|
Incidence of major adverse events
Time Frame: 6 and 12 months
|
Major adverse events (death, stroke)
|
6 and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael Lichtenberg, Dr.med., Klinikum Hochsauerland GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ASL202002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.